Roberto Borea MD
LightNews LightNews
banner
robertoboreamd.bsky.social
Roberto Borea MD
@robertoboreamd.bsky.social
650 followers 71 following 36 posts
Medical Oncologist, PhD student
Focused on lung and breast cancer translational medicine 🧬

Currently working in LB in Malapelle’s Lab 🩸
Posts Replies Media Videos
Reposted by Roberto Borea MD
islb.info
🩸🚀 New Insights in Liquid Biopsy! 🧬

The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis.

🔗 Read the full article here
www.journalofliquidbiopsy.com/article/S295...
International Society of Liquid Biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors
Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing acc...
www.journalofliquidbiopsy.com
May 31, 2025 at 6:16 AM
robertoboreamd.bsky.social
🚨Excited to represent the @islb.info at #ASCO25!

Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸

@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
May 27, 2025 at 4:07 PM
robertoboreamd.bsky.social
#TME in #NSCLC shapes therapy resistance and progression

- a tumor can have two immune niches: rich and poor
- more than immune cells: CAFs, TAMs, DCs, T, NK..
- patient-specific determinants modulate the TME

🔍emerging technologies

www.nature.com/articles/s41...
May 19, 2025 at 9:12 PM
Reposted by Roberto Borea MD
yvonnediaz.bsky.social
Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong.

Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer
The article titled "Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial" presents findings from a clinical study evaluating the efficacy and safety of combining alectinib, an ALK tyrosine kinase inhibitor, with bevacizumab, an anti-angiogenic agent, in treating advanced ALK-rearranged non-small cell lung cancer (NSCLC). Nature Here are five key takeaways from the study: Enhanced Progression-Free Survival (PFS): The combination therapy achieved a 12-month PFS rate of 97.1% and a 36-month PFS rate of 64.2%, indicating a potential improvement over historical data for alectinib monotherapy. Nature High Overall Response Rate (ORR): All 41 patients in the study responded to the treatment, with 87.8% achieving partial responses and 12.2% achieving complete responses, resulting in a 100% ORR. Nature Intracranial Efficacy: The therapy demonstrated significant activity in the central nervous system, with a 36-month intracranial PFS rate of 87.8%, suggesting effectiveness in preventing or delaying brain metastases. Nature Manageable Safety Profile: While 46.3% of patients experienced grade 3–4 adverse events, including proteinuria and hepatotoxicity, no fatal events were reported, and quality of life improved over the course of treatment. Nature Need for Further Research: The promising results support the rationale for conducting randomized controlled trials to compare this combination therapy directly with existing standard treatments and to further assess its benefits and risks. Nature These findings suggest that the combination of alectinib and bevacizumab may offer a potent first-line treatment option for patients with advanced ALK-rearranged NSCLC, warranting further investigation in larger, randomized studies
May 18, 2025 at 11:30 AM
robertoboreamd.bsky.social
💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.

Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo

48% asian, 39% white.
9% discontinued due to side effects

@oncoalert.bsky.social
May 19, 2025 at 8:31 PM
robertoboreamd.bsky.social
📰EGFR-TKI resistance in LUAD isn’t always genetic.
- 39 pts-derived organoids
- 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss.
- Knockout of NKX2-1 → basal-shift + Osim res
- These tumors often lose CDKN2A/B

pbs.twimg.com/media/Gq6QwX...
May 14, 2025 at 12:44 PM
Reposted by Roberto Borea MD
christianrolfo.bsky.social
Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social
May 12, 2025 at 6:30 PM
robertoboreamd.bsky.social
🔬📈 Check out our new commentary on Selinexor (an XPO1 inhibitor) + ICIs in uveal melanoma patients in a phase  1B trial!
➡️12m OS 55 % 
➡️0 % ORR
➡️manageable safety profile
@christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social #CarlosAyala

pmc.ncbi.nlm.nih.gov/articles/PMC...
Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?
pmc.ncbi.nlm.nih.gov
May 5, 2025 at 7:45 PM
Reposted by Roberto Borea MD
rolfolab.bsky.social
New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social
May 5, 2025 at 1:52 PM
Reposted by Roberto Borea MD
rolfolab.bsky.social
Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism”
@OSUCCC_James

@osuwexmed.bsky.social
@christianrolfo.bsky.social
@theaacr.bsky.social
pbs.twimg.com/media/Gpay9i...
April 26, 2025 at 11:42 AM
robertoboreamd.bsky.social
Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬

LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/

@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
April 21, 2025 at 7:51 PM
Reposted by Roberto Borea MD
christianrolfo.bsky.social
Congrats Roberto! And welcome to @rolfolab.bsky.social !!!
robertoboreamd.bsky.social Roberto Borea MD @robertoboreamd.bsky.social · Apr 11
Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅

Grateful for the chance to meet with exceptional people 👐

@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
April 11, 2025 at 11:05 AM
robertoboreamd.bsky.social
Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬

Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social

Exciting discussions shaping the future of #lungcancer testing! 📚
April 12, 2025 at 4:32 PM
robertoboreamd.bsky.social
Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅

Grateful for the chance to meet with exceptional people 👐

@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
April 11, 2025 at 1:49 AM
robertoboreamd.bsky.social
As always, an insightful presentation by @UmbertoMalapelle

➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social

We must continue this path to improve treatment selection!

@islb.info #precisiononcology #lungcancer

⬇️ Key message
March 27, 2025 at 10:15 AM
robertoboreamd.bsky.social
Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights!

@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige
March 25, 2025 at 9:34 PM
robertoboreamd.bsky.social
📢 5-year outcomes from EMPOWER-Lung 1: 1L cemiplimab vs chemo in PD-L1 high (≥50%) NSCLC!

👫🏻 565 pts; 1 vs 1
✅ mOS favors cemiplimab: 26.1 vs 13.3m (HR 0.59), 38.8m in PD-L1 ≥90%
✅ PFS 8.1 vs 5.3m (HR 0.50)
✅ 5y OS rate: 29% vs 15%

www.jto.org/article/S155...

#Immunotherapy #NSCLC
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
Earlier results from the phase 3 EMPOWER-Lung 1 trial demonstrated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab monotherapy versus chemotherapy for ...
www.jto.org
March 19, 2025 at 11:06 AM
robertoboreamd.bsky.social
What a great news! Finally we have a journal dedicated to liquid biopsy research! I am truly excited. 🔥
islb.info International Society of Liquid Biopsy @islb.info · Mar 18
🎉🩸 Thrilled to share that the Journal of Liquid Biopsy is now officially live in PubMed and PMC! A significant step forward for JLB

Check it out here: pmc.ncbi.nlm.nih.gov/journals/?te...

#LiquidBiopsy #PubMed @christianrolfo.bsky.social @yukselurun.bsky.social @eloisajantus.bsky.social
March 18, 2025 at 4:22 PM
Reposted by Roberto Borea MD
islb.info
📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸
Read more: doi.org/10.1016/j.crit…#LiquidBiopsysy
@christianrolfo.bsky.social
March 18, 2025 at 2:46 PM
robertoboreamd.bsky.social
🚨 Out in @natrevclinoncol.bsky.social

📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view

nature.com/articles/s41...

@christianrolfo.bsky.social @osucccjames.bsky.social
March 17, 2025 at 12:00 PM
robertoboreamd.bsky.social
Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨

It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!

bit.ly/43JzN03

@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
March 14, 2025 at 3:48 PM
robertoboreamd.bsky.social
Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology

@rolfolab.bsky.social @oncoalert.bsky.social
March 13, 2025 at 3:25 PM
robertoboreamd.bsky.social
Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer!
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social

➡️ hubs.la/Q03bqnlB0
March 12, 2025 at 7:35 AM
robertoboreamd.bsky.social
The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer!

@christianrolfo.bsky.social @rolfolab.bsky.social
@osucccjames.bsky.social
#HER2 #IHC #Targettherapy
oncoalert.bsky.social The OncoAlert Network 🚨 @oncoalert.bsky.social · Mar 10
JOIN US for a discussion on HER2🧬testing & evolving role of IHC🔬 in hashtag#LungCancer & hashtag#OvarianCancer

REGISTER HERE👇👇
buff.ly/7F6ztd4

JOIN US TUESDAY MARCH 11, 2025
March 11, 2025 at 1:01 PM
robertoboreamd.bsky.social
✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social
March 5, 2025 at 6:32 PM